Gene Silencing Market Size, Share, Trends, Growth and Forecast 2034

Gene Silencing Industry Perspective:

The global gene silencing market size was worth around USD 9.92 billion in 2024 and is predicted to grow to around USD 35.49 billion by 2034 with a compound annual growth rate (CAGR) of roughly 13.60% between 2025 and 2034.

Request Free Sample

Key Insights:

• As per the analysis shared by our research analyst, the global gene silencing market is estimated to grow annually at a CAGR of around 13.60% over the forecast period (2025-2034)
• In terms of revenue, the global gene silencing market size was valued at around USD 9.92 billion in 2024 and is projected to reach USD 35.49 billion, by 2034.
• The market is projected to grow at a significant rate due to the growing number of patients with chronic illnesses and neurological disorders.
• Based on the type, the transcriptional segment is growing at a high rate and will continue to dominate the global market as per industry projections.
• Based on the application, the neurological disease segment is anticipated to command the largest market share.
• Based on region, North America is projected to dominate the global market during the forecast period.

Gene Silencing Market: Overview

Gene silencing refers to the process of artificially or naturally controlling gene expressions. According to market research, gene silencing is a novel medical care technique. It leverages the body's automatic process of controlling diseases by silencing or suppressing specific genes associated with a medical condition. Several types of gene silencing methods currently exist in the healthcare sector. One of the major areas in gene silencing gaining higher attention from the medical research community is the biological process of RNA interference. Gene therapy and gene silencing are two different techniques and the latter is gaining higher growth momentum in research & studies across the globe.

During the forecast period, investments in green silencing are expected to grow due to the rising demand for more effective medical treatments for chronic and neurological conditions such as cancer and neurological diseases.

Moreover, rising investments in the development of novel agricultural crops with higher resistance to evolving diseases will further affect market revenue in the long run. The market is expected to register growth limitations due to the novelty associated with the technology and limited research worldwide. Competition from alternate technologies may further affect market growth trends in the future.

Gene Silencing Market: Growth Drivers

Growing number of patients with chronic illnesses and neurological disorders to promote market revenue

The global gene silencing market is expected to be driven by the rising number of patients worldwide with serious chronic illnesses. For instance, cancer is one of the world's most widely prevalent serious medical conditions with a high fatality rate. Every year millions of people are diagnosed with some form of cancer ranging from breast cancer to salivary gland cancer.

Moreover, the lack of effective cancer treatments has also burdened the existing healthcare infrastructure worldwide leading to increased investments in the development of robust cancer treatments. Gene silencing is a novel medical technique showing promising results in treating cancer and certain rare neurological conditions such as Huttington’s disease.

In January 2025, researchers in China aimed at silencing the mutant human HTT exon 1 which is a huntingtin-encoding gene. The researchers used CasRx which is a programmable CRISPR–Cas system targeting RNA for efficient splicing modulation and knockdown. The scientists tested the strategy across models including a mouse model of HD known as HD 140Q-KI mice, human embryonic kidney (HEK) 293T cells, and a pig model of HD.

Growing development of new medical research facilities and government support remain essential growth drivers

In the last decade, investments in medical research have improved across the globe. An increasing number of patients, the emergence of several critical and fatal medical conditions, a growing number of deaths due to existing medical problems, and other factors have encouraged investments in novel medical treatments and techniques. In April 2025, the University of Nebraska Medical Center announced that it had recently received awards and grants worth USD 5 million in new funding.

In February 2025, China Medical University announced the launch of a new Artificial Intelligence (AI)--driven drug discovery and cancer therapy in partnership with the Healthcare System. The increasing use of next-generation technologies in medical research including AI and machine learning (ML) will further help the global gene silencing market thrive in the coming years.

Gene Silencing Market: Restraints

Technique novelty and limited awareness to restrict market expansion in the future

The global gene silencing industry is expected to be restricted due to the novelty of the technique. Gene silencing is an upcoming medical procedure and it has registered limited adoption worldwide. Silencing biological genes is a sophisticated medical process and requires extensive expertise in the field along with access to sophisticated medical equipment. Limited awareness about gene silencing techniques and their advantages especially in countries that lack advanced medical research infrastructure may impact market revenue in the long run.

Gene Silencing Market: Opportunities

Rising demand for next-generation crops to create growth opportunities for the industry players

The global gene silencing market is anticipated to generate growth opportunities due to the growing demand for climate and disease-resistant crops. In the last few years, evolutions of crop diseases have led to several losses in the agricultural sector. In addition to this, changes in climate conditions due to global warming and rising rates of pollution have further impacted overall crop yield across the globe. According to the United States Department of Agriculture – National Institute of Food and Agriculture (USDA-NIFA), around 205 to 40% of global crop production is lost due to pest infestation.

However, the global demand for crops and agricultural produce is growing rapidly as the world population continues to rise. These factors have generated extra emphasis on the development of disease and climate-resistant crops. Industry players are working on developing techniques such as host-induced gene silencing (HIGS) and spray-induced gene silencing (SIGS) to develop crops with high nutritional value while also promoting improved sustainability in the agricultural sector.

In May 2025, the Minister of Agriculture and Food Sovereignty Annie Genevard and the European Investment Fund signed agreements with 4 banking groups. The agencies have collaborated for the second roll-out phase of the National Initiative for French Agriculture (INAF). It is expected to generate a total fund of EUR 2 billion in the coming years and help more than 15,000 farmers in the region by 2028.

Gene Silencing Market: Challenges

Regulatory hurdles and competition from other alternate techniques to challenge market expansion

The global gene silencing industry is expected to be challenged by the presence of a complex and dynamic regulatory environment worldwide concerning the technique. Moreover, increasing investments in alternate medical treatments such as gene therapy, protein degradation technologies, and DNA editing may affect the final revenue generated by the market players.

Gene Silencing Market: Report Scope

Gene Silencing Market: Segmentation

The global gene silencing market is segmented based on type, application, and region.

Based on type, the global market segments are post-transcriptional, transcriptional, and meiotic. In 2024, the highest growth was listed in the transcriptional segment holding control over 54.05% of the total revenue. It deals with silencing the target gene at the DNA level and involves procedures such as histone modifications or DNA methylation. The post-transcriptional segment is expected to deliver a CAGR of 8.81% during the projection period.

Based on the application, the global market segments are neurological disease treatment, cancer treatment, scar treatment, research, agriculture, and others. In 2024, around 41.04% of the global share was dominated by the neurological disease segment. The growing number of patients worldwide with common and rare neurological disorders is propelling segmental demand. The same trend can be expected in the future according to research.

Gene Silencing Market: Regional Analysis

North America to dominate the market during the forecast period

The global gene silencing market will be led by North America during the forecast period. In 2024, the region dominated around 44.05% of the global revenue with the US taking the regional lead. The presence of robust healthcare and research & development (R&D) infrastructure is propelling regional revenue. North America enjoys the benefits of considerable investments in the R&D of novel medical techniques, drugs, and diagnostic solutions.

Furthermore, the expansion of the regional biotechnology industry driven by strong government regulatory support and a growing environment fostering innovation will further facilitate regional expansion in the future. Asia-Pacific is a growing market with high growth potential during the forecast period. It is expected to generate a CAGR of 9.61% during the projection period. The growing population across Asia-Pacific along with rising investments in regional healthcare will facilitate regional expansion.

Moreover, the Asia-Pacific biotechnology industry is witnessing a growing rate of investments from private companies and government bodies further encouraging higher revenue in the region. In addition to this, the prevalence of patients with chronic illnesses and the rising demand for effective treatments against neurological diseases may facilitate higher revenue in the Asia Pacific.

Gene Silencing Market: Competitive Analysis

The global gene silencing market is led by players like:

• Phio Pharmaceuticals
• Alnylam Pharmaceuticals
• Ionis Pharmaceuticals
• Benitec Biopharma
• miRagen Therapeutics
• Gradalis
• Arcturus Therapeutics
• Sirnaomics
• Arrowhead Pharmaceuticals
• OliX Pharmaceuticals
• Silence Therapeutics
• Silenseed
• Dicerna Pharmaceuticals
• Quark Pharmaceuticals
• Sylentis

The global gene silencing market is segmented as follows:

By Type

• Post-Transcriptional
• Transcriptional
• Meiotic

By Application

• Neurological Disease Treatment
• Cancer Treatment
• Scar Treatment
• Research
• Agriculture
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa